Recommendations for measuring HIV reservoir size in cure-directed clinical trials

Nat Med. 2020 Sep;26(9):1339-1350. doi: 10.1038/s41591-020-1022-1. Epub 2020 Sep 7.

Abstract

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to cause viral rebound after antiretroviral-therapy cessation in assessing the results of cure-directed strategies in vivo. Current measurements assess various aspects of the HIV provirus and its functionality and produce divergent results. Here, we provide recommendations from the BEAT-HIV Martin Delaney Collaboratory on which viral measurements should be prioritized in HIV-cure-directed clinical trials.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Anti-Retroviral Agents / therapeutic use*
  • CD4-Positive T-Lymphocytes / virology
  • Clinical Trials as Topic
  • Disease Reservoirs / virology*
  • HIV Infections / diagnosis*
  • HIV Infections / drug therapy*
  • HIV-1 / drug effects*
  • Humans
  • Mass Screening / methods
  • Viral Load / drug effects
  • Virus Latency / drug effects

Substances

  • Anti-Retroviral Agents

Grant support